Screener
Ashland ASH Intermediates And Solvents — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ashland in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Ashland’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:17 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324226
| (In millions - unaudited) | Three months ended / June 30 / 2026 | Three months ended / June 30 / 2025 | Nine months ended / June 30 / 2026 | Nine months ended / June 30 / 2025 |
|---|---|---|---|---|
| Life Sciences | $4 | $4 | $11 | $12 |
| Personal Care | 6 | 6 | 17 | 19 |
| Specialty Additives | 4 | 3 | 10 | 8 |
| Intermediates | — | — | 1 | — |
| Total operating segments | 14 | 13 | 39 | 39 |
| Unallocated and other | 1 | — | 2 | 2 |
| $15 | $13 | $41 | $41 | |
| Amortization expense |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ashland's intermediates and solvents — research and development expense?
- Ashland (ASH) reported intermediates and solvents — research and development expense of $0 in Q2 2026.
- What does intermediates and solvents — research and development expense mean?
- This metric tracks the investment made by the Intermediates and Solvents segment into innovation, product development, and technical improvements. It indicates the segment's commitment to long-term competitiveness and the evolution of its specialty material offerings.
Ask your AI about Ashland's intermediates and solvents — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude